84,000 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Readystate Asset Management LP

Readystate Asset Management LP bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 84,000 shares of the company's stock, valued at approximately $3,687,000. Readystate Asset Management LP owned approximately 0.15% of Structure Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Sandia Investment Management LP acquired a new stake in Structure Therapeutics during the 2nd quarter valued at approximately $39,000. Assetmark Inc. grew its stake in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares in the last quarter. Quarry LP acquired a new stake in Structure Therapeutics during the 2nd quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new stake in Structure Therapeutics during the 3rd quarter valued at approximately $202,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Morgan Stanley assumed coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. HC Wainwright assumed coverage on Structure Therapeutics in a research note on Wednesday. They set a "buy" rating and a $80.00 price objective for the company. JMP Securities decreased their target price on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $85.67.

Structure Therapeutics Stock Down 7.6 %

Shares of GPCR traded down $2.55 during mid-day trading on Thursday, hitting $31.00. The stock had a trading volume of 478,087 shares, compared to its average volume of 781,555. The company has a market cap of $1.78 billion, a PE ratio of -41.89 and a beta of -3.41. The company's fifty day simple moving average is $37.66 and its two-hundred day simple moving average is $39.38. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $63.30.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.